PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s stock price traded down 2.4% during trading on Tuesday . The company traded as low as $1.59 and last traded at $1.60. 13,274 shares were traded during mid-day trading, an increase of 50% from the average session volume of 8,831 shares. The stock had previously closed at $1.64.
PharmaCyte Biotech Stock Up 15.6 %
The stock has a 50 day moving average of $1.79 and a 200 day moving average of $1.91.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Further Reading
- Five stocks we like better than PharmaCyte Biotech
- Technology Stocks Explained: Here’s What to Know About Tech
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Earnings Per Share Calculator: How to Calculate EPS
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Options Trading – Understanding Strike Price
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
